
September 16, 2022
Hepatologist Naim Alkhouri and Endocrinologist Scott Isaacs join Ken Cusi and Roger Green to discuss drug choices prescribers can make TODAY for patients with Type 2 Diabetes Mellitus and obesity that have positive impact on Fatty Liver disease.
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
This episode From the Vault comes from Season 3, Episode 39.4. Ian Rowe’s decision curve model does an excellent job of modeling the success rate and cost effectiveness of modeling early NASH diagnosis. However, as Louise Campbell points out, simply getting the patient diagnosed does not mean therapeutic success, which has implications for the early diagnosis model and broader patient management issues.
In the Season 3 NAFLD Year-in-Review conversations series, Surfers Jörn Schattenberg, Louise Campbell and Roger Green embark on a string of interviews with a handful of Key Opinion Leaders who made headlines and advances in Fatty Liver disease in 2022. In this exclusive segment, Naim Alkhouri joins Louise and Roger to discuss drugs, NITs, digital diagnostics and the importance of preventing pediatric and adolescent NAFLD.
Surfing the NASH Tsunami hosts its annual NAFLD Year-in-Review over the second half of December. For the final installment of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Naim Alkhouri, Stephen Harrison and Ian Rowe to discuss putting a dent in Fatty Liver disease in 2022 and beyond.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Louise Campbell and Roger Green are joined by Jeff Lazarus to discuss a “drugs-plus” approach to liver disease, interprofessional collaboration, guidelines and much more.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Louise Campbell and Roger Green are joined by Ken Cusi to discuss two major trends: publication and adoption of guidelines and clinical care pathways that increase requirements from screening in primary care and endocrinology settings, and promising Phase 3 trials that suggest new NASH drugs are on a shorter-term horizon.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Mazen Noureddin to reflect on opening a new research institute, increasing optimism around drug trials and the use of NITs, work in the novel mitochondrial uncoupling agent HU6, the NAIL-NIT consortium and more.
Surfing the NASH Tsunami hosts its annual NAFLD Year-in-Review over the second half of December. For the second installment of this Season 3 finale, Surfers Jörn Schattenberg, Louise Campbell and Roger Green interview Mazen Noureddin, Ken Cusi and Jeff Lazarus to discuss putting a dent in Fatty Liver disease in 2022 and beyond.